Zacks reaffirmed their neutral rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued to investors on Thursday, Analyst Ratings Network.com reports. The firm currently has a $78.00 price target on the stock.
Zacks’ analyst wrote, “Gilead made a strong start to 2014, with both revenues as well as earnings beating expectations by huge margins in the first quarter of the year. The company’s first-quarter 2014 earnings (including stock-based compensation) of $1.44 per share blew past the Zacks Consensus Estimate of $0.75 per share. The massive earnings outperformance was attributable to the exceptional performance of Sovaldi in its first full quarter in the market. Sovaldi’s strong sales ($2.27 billion) helped Gilead record total revenues of $5 billion, easily surpassing the Zacks Consensus Estimate of $4 billion. We expect Sovaldi sales to continue growing throughout 2014. We continue to have a Neutral stance on the stock. Our target price is $78.00 per share.”
In other Gilead Sciences news, EVP Norbert Bischofberger unloaded 90,000 shares of Gilead Sciences stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $67.03, for a total value of $6,032,700.00. Following the completion of the transaction, the executive vice president now directly owns 119,302 shares in the company, valued at approximately $7,996,813. The sale was disclosed in a legal filing with the SEC, which is available at this link.
GILD has been the subject of a number of other recent research reports. Analysts at Nomura reiterated a buy rating on shares of Gilead Sciences in a research note on Wednesday. They now have a $130.00 price target on the stock. Separately, analysts at Guggenheim raised their price target on shares of Gilead Sciences from $104.00 to $113.00 in a research note on Wednesday. Finally, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $132.00 to $135.00 in a research note on Wednesday. They now have a buy rating on the stock. Four equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $88.76.
Gilead Sciences (NASDAQ:GILD) traded down 0.05% on Thursday, hitting $74.04. The stock had a trading volume of 20,018,490 shares. Gilead Sciences has a one year low of $46.70 and a one year high of $84.88. The stock’s 50-day moving average is $73.23 and its 200-day moving average is $73.87. The company has a market cap of $113.8 billion and a price-to-earnings ratio of 27.44.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $6.01 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
To view Zacks’ full report, visit Zacks’ official website.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.